Drug Profile
Research programme: autoimmune disorders - Abbott Laboratories
Latest Information Update: 23 Jan 2013
Price :
$50
*
At a glance
- Originator Abbott Laboratories; PDL BioPharma
- Developer Abbott Laboratories
- Class
- Mechanism of Action Interleukin 12 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Autoimmune disorders